CD24 is known to play a role in immune regulation and inflammation, and the trial demonstrated that CD24 overexpressing EVs were well tolerated, with no treatment-related adverse events; reduced key inflammatory markers by 50% in the majority of patients; and improved the respiratory rate as well as oxygen saturation in COVID-19 patients [166]. The gene discussed is CD24; the disease is COVID-19.